FDA delays approval for Moderna RSV vaccine

Sharing is Caring!

Moderna, Inc. (NASDAQ:MRNA) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that due to administrative constraints, the agency does not expect to complete its review of the Biologics License Application (BLA) for mRNA-1345, Moderna’s investigational respiratory syncytial virus (RSV) vaccine, by the previously communicated Prescription Drug User Fee Act (PDUFA) date of May 12, 2024. The FDA has informed Moderna that it is working to conclude the review by the end of May 2024.

See also  Why Congress has a 7% Approval Rating – Corruption
See also  Bill Maher and Robert Kennedy debate the covid vaccine on HBO.

investors.modernatx.com/news/news-details/2024/Moderna-Announces-Update-on-Investigational-RSV-Vaccine/default.aspx

h/t A Deplorable Neanderthal

Views: 92

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.